Details for New Drug Application (NDA): 061763
NDA 061763 describes VELOSEF '250', which is a drug marketed by Ersana and Apothecon and is included in two NDAs. Additional details are available on the VELOSEF '250' profile page.
The generic ingredient in VELOSEF '250' is cephradine. There is one drug master file entry for this compound. Additional details are available on the cephradine profile page.
The generic ingredient in VELOSEF '250' is cephradine. There is one drug master file entry for this compound. Additional details are available on the cephradine profile page.
Summary for 061763
| Tradename: | VELOSEF '250' |
| Applicant: | Apothecon |
| Ingredient: | cephradine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061763
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 125MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 250MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
